Kidney Stone (Nephrolithiasis) Treatment

1. Acute Management (Passing a Stone)

Pain Relief

The priority in acute renal colic is analgesia. NSAIDs (e.g., ketorolac, ibuprofen) are first-line; opioids are used when NSAIDs are insufficient or contraindicated. IV hydration is given when the patient cannot tolerate oral fluids.

Medical Expulsive Therapy (MET)

α-blockers (e.g., tamsulosin) and calcium channel blockers reduce dysmotile ureteric contractions while preserving expulsive peristaltic activity, facilitating stone passage — particularly for distal ureteral stones ≤10 mm.

When to Intervene Urgently

A UTI in the setting of ureteral obstruction is a medical emergency requiring immediate drainage via ureteral stent or percutaneous nephrostomy tube. Other indications for urgent intervention: intractable pain/vomiting, solitary kidney, bilateral obstruction, AKI.

2. Surgical / Procedural Treatment

Treatment selection depends primarily on stone size, location, composition (CT attenuation), and patient anatomy.

Stone Burden Classification (Campbell-Walsh Urology)

Stone Size	Preferred Approach
≤1 cm	SWL (first-line) or flexible URS (equally acceptable, per EAU/AUA guidelines)
1–2 cm	SWL or URS; PCNL if lower-pole or high-attenuation
>2 cm	PCNL preferred; SWL/URS may be used adjunctively
Staghorn calculi	PCNL (often staged)

Extracorporeal Shock Wave Lithotripsy (ESWL)

Non-invasive; fragments stones <2 cm using focused high-energy shock waves
Stone-free rates: ~80–88% for renal pelvis/UPJ stones, ~70% for upper/mid calyces, only 35–69% for lower pole stones
Less effective for: stones with CT attenuation ≥900 HU, lower-pole location, obesity, anatomic anomalies
Contraindications: pregnancy, uncorrected coagulopathy, aortic aneurysm, distal obstruction

Ureteroscopy (URS) / Retrograde Intrarenal Surgery (RIRS)

Flexible URS now a co-equal first-line option for stones ≤1 cm (EAU/AUA guidelines)
Laser lithotripsy (holmium or thulium fiber laser) fragments the stone for retrieval or dusting
Avoids ionizing radiation concerns; useful when SWL is contraindicated
Generally avoided in children <5 years

Percutaneous Nephrolithotomy (PCNL)

Gold standard for stones >2 cm, lower-pole stones, ESWL-refractory stones, staghorn calculi
Creates a dilated percutaneous tract into the kidney for stone extraction
Higher stone-free rates than SWL/URS for large stones, but more invasive with higher complication risk (bleeding, infection)
Mini-PCNL, ultra-mini, and micro-PCNL variants available for smaller stones

Open/Laparoscopic Surgery

Rarely necessary; reserved for anatomic abnormalities (e.g., ureteropelvic junction obstruction requiring simultaneous repair) where endoscopic approaches fail

3. Stone-Type-Specific Medical Prevention

Calcium Oxalate Stones (most common, ~80%)

Intervention	Mechanism
High fluid intake (>2.5 L/day urine output)	Reduces urinary supersaturation
Normal dietary calcium (1000–1200 mg/day with meals)	Binds intestinal oxalate, reduces absorption
Low sodium (<2.5 g/day)	Reduces urinary calcium excretion
Low animal protein	Reduces Ca excretion, increases citrate
Thiazide diuretics (e.g., hydrochlorothiazide, chlorthalidone)	Reduces urinary Ca by ~50%; requires dietary Na restriction
Potassium citrate	Raises urinary citrate (natural inhibitor); alkalinizes urine
Allopurinol	Reduces stone recurrence in those with hyperuricosuria + CaOx stones

Avoid: high-dose vitamin C supplements (increases endogenous oxalate), high-oxalate foods (spinach, rhubarb, almonds), calcium supplements outside of meals.

Calcium Phosphate Stones

Urine pH is the key driver (forms at pH >6.5)
Thiazides to reduce hypercalciuria; avoid excessive alkali therapy
Evaluate for primary hyperparathyroidism, distal RTA

Uric Acid Stones

Urine alkalinization to pH 6.0–6.5 (potassium citrate or sodium bicarbonate) is highly effective — can dissolve existing stones
Reduce purine-rich foods; allopurinol if hyperuricemia/hyperuricosuria persists
Increase fluid intake

Struvite (Infection) Stones

Caused by urease-producing bacteria (Proteus mirabilis, Klebsiella)
Complete surgical removal is essential (PCNL) — fragments left behind perpetuate infection
Antibiotics targeted to the organism
Acetohydroxamic acid (AHA) — urease inhibitor — used in refractory cases

Cystine Stones

Very high fluid intake (~4 L/day including nocturnal) to keep cystine <243 mg/L
Urine alkalinization to pH >7.0 (potassium citrate)
D-penicillamine or tiopronin (α-mercaptopropionylglycine) — chelating agents that increase cystine solubility
These stones are often ESWL-resistant; PCNL or URS preferred

Primary Hyperoxaluria (Type I)

Lumasiran or nedosiran — siRNA-based therapies that reduce hepatic oxalate generation (approved in recent years)

4. General Preventive Measures (All Stone Types)

Fluid intake: Target >2.5 L/day urine output; distribute throughout the day and at night
Dietary calcium: Normal intake (1000–1200 mg/day) — restriction is harmful, not protective
Low sodium: <2.5 g/day reduces calciuria
Moderate animal protein: Reduces calciuria and increases citruria
DASH-style diet (high fruit/vegetable, low animal protein): Associated with reduced stone risk
Metabolic workup after first stone (especially in high-risk patients): 24-hour urine collection for calcium, oxalate, citrate, uric acid, sodium, volume

5. Special Populations

Children: Ultrasound preferred for imaging (avoids radiation); MET and ESWL/URS/PCNL used based on size; full metabolic workup mandatory
Pregnancy: ESWL contraindicated; URS is safest procedural option; conservative management first
Solitary kidney / bilateral obstruction: Lower threshold for urgent drainage

Sources:

Harrison's Principles of Internal Medicine, 22e (2025), Ch. 330: Nephrolithiasis
Campbell-Walsh-Wein Urology, Ch. 93: Treatment Decision by Stone Burden
Brenner & Rector's The Kidney — Urolithiasis, Dietary & Pharmacologic Management
Bailey and Love's Short Practice of Surgery, 28e — Urolithiasis

Recent evidence (2024–2026):

A 2026 systematic review in Annals of Internal Medicine specifically addresses prevention of recurrent nephrolithiasis in adults and children (PMID 41871357) — consistent with the dietary and pharmacologic strategies above.

This is a shared conversation. Sign in to Orris to start your own chat.